Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Activated phosphoinositide-3-kinase delta syndrome (APDS) is a primary immunodeficiency characterized by immune dysregulation.
• Genetic mutations leading to PI3Kδ overactivation are the underlying cause of APDS.
• Current management involves supportive therapies and pathway modulation.

Purpose of the Study:

• To review the biology of the PI3K pathway in the context of APDS.
• To discuss clinical strategies for modulating the PI3K pathway in APDS.
• To highlight differences between PI3K inhibition in APDS and hematological malignancies.

Main Methods:

• Literature review of PI3K pathway biology.
• Analysis of clinical data regarding APDS treatments.
• Comparison of therapeutic approaches for APDS and hematological malignancies.

Main Results:

• Sirolimus, an mTOR inhibitor, shows efficacy for certain APDS manifestations.
• Leniolisib, a specific PI3Kδ inhibitor, demonstrates promising early clinical results.
• Targeted PI3Kδ inhibition offers a potentially more precise therapeutic strategy for APDS.

Conclusions:

• Nuanced modulation of the PI3K pathway is crucial for effective APDS management.
• Leniolisib represents a significant advancement in targeted APDS therapy.
• Understanding PI3K pathway differences is key for optimizing treatment in APDS versus hematological cancers.